Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-associated Antigen Recognized by m170 Monoclonal Antibody
- Molecular classification
- Cell surface antigen
01
Overview
The tumor-associated antigen recognized by the m170 monoclonal antibody is a cell-surface molecule expressed on adenocarcinomas, including prostate and breast cancer cells. While the precise molecular identity remains unspecified at the gene/protein level, its expression enables targeted delivery of therapeutic agents or radioisotopes to tumor cells for imaging and treatment. Radiolabeled m170 has been used in clinical trials for radioimmunotherapy, demonstrating specific localization to metastatic sites with manageable toxicity profiles. Combining radioimmunotherapy using m170 with chemotherapeutic agents such as paclitaxel can enhance efficacy but may increase hematologic toxicity.
- Other names
- m170 antigenm170 target
02
Mechanism of action
Targeted radiation delivery to tumor cells via radiolabeled m170. Possible antibody-dependent cell-mediated cytotoxicity (ADCC).
03
Biological functions
Cell adhesionCell signalingTumor cell survivalTumor metastasis
04
Disease associations
CancerMetastasisProstate CancerBreast Cancer
05
Safety considerations
Marrow suppression (myelosuppression)Immunogenicity of murine antibody (HAMA response)Hematologic toxicity when combined with chemotherapy
06
Interacting drugs
111In-m170
2 more in the full profile.
07
Biomarkers
Antigen expression level in tumor tissue for patient selectionTumor size reductionMetastasis reduction
Beyond the preview
Go deeper on Tumor-associated Antigen Recognized by m170 Monoclonal Antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-associated Antigen Recognized by m170 Monoclonal Antibody.